Genomic correlate of exceptional erlotinib response in head and neck squamous cell carcinoma
EM Van Allen, VWY Lui, AM Egloff, EM Goetz… - JAMA …, 2015 - jamanetwork.com
Importance Randomized clinical trials demonstrate no benefit for epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitors in unselected patients with head and neck
squamous cell carcinoma (HNSCC). However, a patient with stage IVA HNSCC received 13
days of neoadjuvant erlotinib and experienced a near-complete histologic response.
Objective To determine a mechanism of exceptional response to erlotinib therapy in
HNSCC. Design, Setting, and Participants Single patient with locally advanced HNSCC who …
receptor (EGFR) tyrosine kinase inhibitors in unselected patients with head and neck
squamous cell carcinoma (HNSCC). However, a patient with stage IVA HNSCC received 13
days of neoadjuvant erlotinib and experienced a near-complete histologic response.
Objective To determine a mechanism of exceptional response to erlotinib therapy in
HNSCC. Design, Setting, and Participants Single patient with locally advanced HNSCC who …